Clofarabine-based Therapy
Clofarabine-Based Therapy is a chemotherapeutic regimen defined by the inclusion of clofarabine, a nucleoside analog inhibitor of DNA synthesis and ribonucleotide reductase, as the principal cytotoxic agent in the treatment of refractory childhood cancers.
266
Publications
16.4K
Citations
1.7K
Authors
613
Institutions
Publications per year
2017–2026
36
Parents
266
1–5 of 266
1.7K
The University of Texas MD Anderson Cancer Center, United States
43 publications · 4K citations
27
h-index
The University of Texas MD Anderson Cancer Center, United States
23 publications · 4.4K citations
21
h-index
The University of Texas MD Anderson Cancer Center, United States
24 publications · 1.8K citations
17
h-index
The University of Texas MD Anderson Cancer Center, United States
19 publications · 1.6K citations
16
h-index
The University of Texas MD Anderson Cancer Center, United States
18 publications · 1.8K citations
16
h-index
1–5 of 1.7K
613
The University of Texas MD Anderson Cancer Center
Houston, United States
36 h-index
592 publications
47.8K citations
Memorial Sloan Kettering Cancer Center
New York, United States
11 h-index
20 publications
632 citations
Fred Hutch Cancer Center
Seattle, United States
11 h-index
34 publications
1.4K citations
Dana-Farber Cancer Institute
Boston, United States
10 h-index
14 publications
495 citations

Sorbonne Université
Paris, France
10 h-index
21 publications
466 citations

St. Jude Children's Research Hospital
Memphis, United States
10 h-index
43 publications
1.7K citations
Universität Ulm
Ulm, Germany
10 h-index
40 publications
5.8K citations

University of Cologne
Cologne, Germany
10 h-index
46 publications
7.3K citations
1–8 of 613
55 publications · 5.8K citations
27
h-index
Repository · 19 publications · 922 citations
15
h-index
16 publications · 1.8K citations
14
h-index
BJH · 12 publications · 547 citations
12
h-index
15 publications · 423 citations
12
h-index
1–5